Overview
Danon disease is an X-linked recessive disorder characterized by primary LAMP2 gene mutations, leading to cardiomyopathy, skeletal myopathy, and variable cognitive impairment due to lysosomal dysfunction in muscle and cardiac tissues 12.Diagnosis
Genetic testing identifying mutations in the LAMP2 gene is definitive 12.
Elevated serum creatine kinase levels often observed 12.
Muscle biopsy may reveal characteristic histological changes, including vacuolar myopathy 12.
Cardiac MRI or echocardiography can show hypertrophic cardiomyopathy patterns 12.Management
No specific pharmacological treatment exists; management focuses on supportive care 12.
Symptomatic treatment for heart failure with standard heart failure medications (e.g., ACE inhibitors, beta-blockers) as needed 12.
Physical therapy to maintain muscle strength and function 12.
Regular monitoring for complications such as arrhythmias and respiratory failure 12.Special Populations
Limited data; management principles similar across age groups but tailored to specific needs 12.
Cognitive impairment management may require specialized neurological care 12.Key Recommendations
Confirm diagnosis through genetic testing for LAMP2 mutations (Evidence: Expert opinion) 12.
Implement supportive care including physical therapy and symptomatic treatment for heart failure (Evidence: Expert opinion) 12.
Regular multidisciplinary monitoring essential for early detection of complications (Evidence: Expert opinion) 12.References
1 Davis SJ, Wheldrake JF, Freeze HH. An immunological assessment of lysosomal enzymes and other macromolecules sulfated during vegetative growth of Dictyostelium discoideum. Journal of cellular biochemistry 1988. link
2 Judelson HS, Freeze HH, Dimond RL. Characterization and distribution of multiple antigens on N-linked oligosaccharides of Dictyostelium discoideum proteins. Archives of biochemistry and biophysics 1987. link90183-4)